Literature DB >> 18269681

High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.

K Kontou-Fili1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18269681     DOI: 10.1111/j.1398-9995.2007.01604.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  19 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 2.  [Pharmacoprophylaxis and co-medications in allergen-specific immunotherapy].

Authors:  B Wedi; F Ruëff
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

3.  [Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab].

Authors:  D Wieczorek; A Kapp; B Wedi
Journal:  Hautarzt       Date:  2014-09       Impact factor: 0.751

Review 4.  Hymenoptera Allergy and Mast Cell Activation Syndromes.

Authors:  Patrizia Bonadonna; Massimiliano Bonifacio; Carla Lombardo; Roberta Zanotti
Journal:  Curr Allergy Asthma Rep       Date:  2016-01       Impact factor: 4.806

Review 5.  Mastocytosis.

Authors:  Knut Brockow; Dean D Metcalfe
Journal:  Chem Immunol Allergy       Date:  2010-06-01

Review 6.  [Emergency treatment and management of anaphylaxis].

Authors:  K Brockow; J Ring
Journal:  Hautarzt       Date:  2013-02       Impact factor: 0.751

Review 7.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

Review 8.  Use of omalizumab in the treatment of food allergy and anaphylaxis.

Authors:  Jay A Lieberman; Mirna Chehade
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 9.  The problem of anaphylaxis and mastocytosis.

Authors:  Ulrich R Müller; Gabrielle Haeberli
Journal:  Curr Allergy Asthma Rep       Date:  2009-01       Impact factor: 4.806

10.  Anti-immunoglobulin e therapy.

Authors:  Manav Segal; Jeffrey R Stokes; Thomas B Casale
Journal:  World Allergy Organ J       Date:  2008-10       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.